UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cutaneous Melanoma

6th Edition 2020, 2020

Volltextzugriff (PDF)

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression

PloS one, 2011-04, Vol.6 (4), p.e19144-e19144

2011

Volltextzugriff (PDF)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109

Cancers, 2022-09, Vol.14 (18), p.4525

2022

Volltextzugriff (PDF)

Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy

Frontiers in oncology, 2022-01, Vol.11, p.794615-794615

2022

Volltextzugriff (PDF)

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Clinical cancer research, 2020-06, Vol.26 (11), p.2506-2514

2020

Volltextzugriff (PDF)

Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116

European urology, 2023-10, Vol.84 (4), p.e96-e97

2023

Volltextzugriff (PDF)

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1929-1938

2022

Volltextzugriff (PDF)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Volltextzugriff (PDF)

New agents and new targets for renal cell carcinoma

American Society of Clinical Oncology educational book, 2014 (34), p.e222-e227

2014

Volltextzugriff (PDF)

Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (20), p.5459-5459

2019

Volltextzugriff (PDF)

Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women

Annals of behavioral medicine, 2020-01, Vol.54 (1), p.1-9

2020

Volltextzugriff (PDF)

Application of IL-2 and other cytokines in renal cancer

Expert opinion on biological therapy, 2004-04, Vol.4 (4), p.455-468

2004

Volltextzugriff (PDF)

Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Clinical cancer research, 2019-07, Vol.25 (13), p.4194-4194

2019

Volltextzugriff (PDF)

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases

Oncotarget, 2020-08, Vol.11 (33), p.3118-3128

2020

Volltextzugriff (PDF)

A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-α2B in Patients with Metastatic Melanoma

Clinical cancer research, 2002-10, Vol.8 (10), p.3075-3081

2002

Volltextzugriff (PDF)

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1125-A1125

2023

Volltextzugriff (PDF)

Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of Response

Seminars in oncology, 2006-10, Vol.33 (5), p.583-587

2006

Volltextzugriff (PDF)

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Seminars in oncology, 2009-12, Vol.36, p.S26-S36

2009

Volltextzugriff (PDF)

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

Journal for immunotherapy of cancer, 2017-04, Vol.5 (1), p.1-10, Article 38

2017

Volltextzugriff (PDF)

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.578-578

2018

Volltextzugriff (PDF)

Management of metastatic renal cell carcinoma in patients with poor prognosis

Cancer management and research, 2010-05, Vol.2 (default), p.123-132

2010

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4500-4500

2019

Volltextzugriff (PDF)

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.546-546

2019

Volltextzugriff (PDF)

1 – 25 von 452

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Books

ThemaLife Sciences & Biomedicine

ThemaMelanoma - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(363)
Mit Volltextzugriff
(417)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(451)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Humans
(43)
Science & Technology
(31)
Immunotherapy
(20)
Biological And Medical Sciences
(19)
Physical Sciences
(18)
Medical Sciences
(17)
Female
(16)
Melanoma
(16)
Male
(13)
Adult
(12)
Cancer
(12)
Multidisciplinary Sciences
(12)
Science & Technology - Other Topics
(12)
Social Sciences
(12)
Kidney Neoplasms - Drug Therapy
(11)
Kidney Cancer
(10)
Tumors
(10)
Antineoplastic Agents
(9)
Pharmacology. Drug Treatments
(9)
Animals
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Cutaneous Melanoma

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109

Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

New agents and new targets for renal cell carcinoma

Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]

Application of IL-2 and other cytokines in renal cancer

Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases

A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Temozolomide, Interleukin 2, and IFN-α2B in Patients with Metastatic Melanoma

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of Response

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

Management of metastatic renal cell carcinoma in patients with poor prognosis

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B

Aktive Filter

Suchergebnisse filtern